Skip to content

Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial

Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02504203
Acronym
BCGR
Enrollment
2332
Registered
2015-07-21
Start date
2015-11-01
Completion date
2021-06-01
Last updated
2026-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BCG, Infant Mortality

Brief summary

The purpose of this study is to determine whether BCG vaccination shortly after birth can reduce early infant mortality in a rural and an urban setting.

Detailed description

Background: BCG and oral polio vaccines (OPV) at birth are associated with beneficial non-specific effects, reducing neonatal mortality by more than what can be explained by prevention of the target diseases. BCG is recommended at birth, but is often given much later, especially in rural areas. In two RCTs in Guinea-Bissau, BCG-at-birth reduced neonatal mortality in low birthweight (\<2500g; LBW) children by 48% (95%CI: 18-67%) and in children with a birthweight \>2500g (NBW), OPV+BCG vs BCG was associated with a 32% (95%CI: 0-55%) lower mortality. WHO recommends home visits shortly after birth to reduce mortality, but vaccinations are not normally provided. If the vaccines indeed have profound effects on innate immunity and neonatal mortality in both LBW and NBW children many lives could be saved if BCG and OPV was provided earlier. Urban and rural clusters are randomised to home visits with and without vaccinations. All children participating in the study will be offered routine vaccines at village visits by the BHP team in the rural area. In the urban area, BCG and OPV will be provided at follow-up visits if the child has not yet received the vaccines. Thereby the study will provide earlier vaccination for all children. Hypothesis: BCG+OPV at birth provided at village visits shortly after birth will reduce early infant mortality by 40%. Methods: The study will be conducted in Biombo, Oio and Cacheu in rural Guinea-Bissau and in six suburban districts in the capital of Guinea-Bissau. In Guinea-Bissau home visits are not yet implemented as part of the routine program. Pregnant women will be offered to participate in the study at the time of pregnancy registration, which is conducted as part of the routine registration in the rural and urban health and demographic surveillance systems, respectively. Community key informants or mothers will communicate information on births to the BHP study team, and a study nurse will visit every new-born child shortly after a CKI or mother calls, if possible on the same day. Clusters will be randomised to receive immediate vaccination of their children shortly after birth or at the first visit by the BHP team in the rural area and at 2-months follow-up visits in the urban area. Statistical analyses: The primary analysis of early infant non-accidental mortality will be assessed on a PP analysis stratifying for factors used in the randomization (Region, pre-study mortality level (high/low)) and sex, thus allowing different baseline hazards for boys and girls. To account for clustering we will employ cluster-robust variance estimates. For the primary outcome, we will use Cox proportional hazards models, stratified for the above mentioned factors and with age as underlying time-scale. Deaths due to accidents will be censored. The effect of early vaccination will be assessed for the following secondary outcomes: * Non-accidental hospital admission * Severe morbidity (composite outcome of non-accidental mortality and non-accidental hospital admissions) * Consultations * Growth * Mid-upper-arm circumference * Weight-for-age z-score * BCG scarring * Cost-effectiveness of providing BCG and OPV at home visits Based on previous data from the rural HDSS in the areas where the current study will be conducted, the expected proportion of events (deaths and hospitalisation) between day 1 and the next home visit or 60 days of age, whichever comes first is 2.4% (unpublished data). The proportion of events are expected to be at least as high in the urban area. A recent trial in Ghana indicated that three home visits during the first week of life to promote essential new-born care practices and to weigh and assess children for danger signs was associated with an 8% (-12 to 25%) reduction in neonatal mortality. Based on pre-trial mortality data from the same rural clusters, the design effect is measured to be 1.43 (ratio of square of the standard errors for the cluster-adjusted/unadjusted HRs). Thus, in order to obtain 80% power to detect a reduction in early infant severe morbidity if the true reduction of BCG and OPV provided at home visits is larger than 40%, at least 6666 children need to be enrolled.

Interventions

Sponsors

Bandim Health Project
Lead SponsorOTHER
Research Center for Vitamins and Vaccines, Statens Serum Institute
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 72 Years
Healthy volunteers
Yes

Inclusion criteria

• All children registered during pregnancy will be eligible for the study provided they have not yet received BCG at the date of the home visit.

Exclusion criteria

* Children born outside the cluster, and returning more than 72 hours after the delivery * Children that the nurse evaluates to die within the next 24 hours.

Design outcomes

Primary

MeasureTime frameDescription
Non-accidental Mortality60 days after birthNon-accidental mortality between the home visit and the next follow-up visit by BHP, when all unvaccinated children who are home will be offered BCG or the date of registering a non-trial vaccine or 60 days, whichever comes first.

Secondary

MeasureTime frameDescription
Non-accidental Hospital Admission60 days after birthNon-accidental hospital admission between the home visit and the next follow-up visit by BHP, when all unvaccinated children who are home will be offered BCG or the date of registering a non-trial vaccine or 60 days, whichever comes first.
Severe Morbidity60 days after birthComposite outcome of non-accidental mortality and non-accidental hospital admissions
All-cause Consultations60 days after birthAll-cause out-patient consultation between the home visit and the next follow-up visit by BHP, when all unvaccinated children who are home will be offered BCG or the date of registering a non-trial vaccine or 60 days, whichever comes first.
Mid-upper-arm Circumference60 days after birthDevelopment in mid-upper-arm circumference measured using a TALC insertion tape between enrollment and first visit by the BHP team will be assessed.
Weight-for-age Z-score60 days after birthDevelopment in weight between enrolment and first visit by the BHP team will be assessed using the WHO Child Growth Standards. These standards were developed using data collected in the WHO Multicentre Growth Reference Study. A child with a weight-for-age Z-score of 0 has a weight-for-age corresponding to the reference mean. A negative z-score indicates that the childs weight-for-age is below the reference mean, while a child with a positive score is above the mean.
BCG Scarring6 months after birthDevelopment of a BCG vaccination scar (yes/no) will be assessed.
Cost-effectiveness Analysis of Providing BCG at Home-visits60 days after birthA cost effectiveness analysis seeking to measure the cost per death averted using a societal perspective, contrasting the costs of vaccine provision in the present programme and an outreach system as tested in the trial. The costs/savings associated with different rates of consultations and admissions will also be taken into account.
Cause Specific Mortality60 days after birthFor every death a verbal autopsy will be made

Countries

Guinea-Bissau

Contacts

PRINCIPAL_INVESTIGATORSanne M Thysen, MD, PhD

Bandim Health Project

PRINCIPAL_INVESTIGATORAne B Fisker, MD,PhD

Bandim Health Project

PRINCIPAL_INVESTIGATORAmabelia Rodrigues, PhD

Bandim Health Project

STUDY_DIRECTORChristine S Benn, MD,PhD,DMSc

Research Center for Vitamins and Vaccines

STUDY_DIRECTORPeter Aaby, PhD,DMSc

Bandim Health Project

Baseline characteristics

Characteristic
Age, Customized
24-47 hours
511 Participants
Age, Customized
< 24 hours
1230 Participants
Age, Customized
48-71 hours
485 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
1219 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Region of Enrollment
Guinea-Bissau
1219 participants
Sex: Female, Male
Female
1100 Participants
Sex: Female, Male
Male
514 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
7 / 1,00628 / 1,206
other
Total, other adverse events
3 / 8870 / 1,046
serious
Total, serious adverse events
14 / 1,00636 / 1,206

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 27, 2026